Trials / Completed
CompletedNCT01498172
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Patients With Non Muscle Invasive Bladder Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Patrice Jichlinski · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, the investigators would like to assess how intravesical BCG schedules after immunization of non muscle invasive bladder patients with the recMAGE-A3 protein, together with adjuvant AS15 (recMAGE-A3 + AS15 ASCI), may enhance innate and vaccine-specific T cell responses both systemically and locally in the bladder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MAGE-A3 ASCI | 5 doses every 3 weeks |
| BIOLOGICAL | BCG | 1 intravesical dose /week for 6 weeks |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2015-02-01
- First posted
- 2011-12-23
- Last updated
- 2015-02-04
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT01498172. Inclusion in this directory is not an endorsement.